Last reviewed · How we verify
NCT01004809: AVODART®PMS
AVODART® Alopecia Post-marketing Surveillance (PMS)
trial testing Dutasteride in Alopecia in 712 participants. Completed in 21 December 2012.
1 December 2012
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 712 |
| Start date | 29 April 2010 |
| Primary completion | 1 December 2012 |
| Estimated completion | 21 December 2012 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Dutasteride (dutasteride) — full drug profile →
Conditions studied
- Alopecia — all drugs for Alopecia →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 18 to 41, male only, with Alopecia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia.
Choi GS, Kim JH, Oh SY, Park JM, et al · · 2016 · cited 21× · PMID 27489426 · DOI 10.5021/ad.2016.28.4.444
Verify or expand the search:
- PubMed search for NCT01004809
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dutasteride
Trials testing the same drug.
- NCT07417449 — Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP · recruiting
- NCT05599243 — Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia. · Phase 2 · completed
- NCT04947631 — Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia · Phase 3 · completed
- NCT02014584 — Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia · Phase 3 · completed
- NCT01547299 — Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Pr · Phase 2 · completed
Other recruiting trials for Alopecia
Currently open trials in the same condition.
- NCT07422376 — Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variation · NA · recruiting
- NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
- NCT06998680 — 6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair · NA · recruiting
- NCT05484973 — Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss · NA · recruiting
- NCT06215469 — Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) · NA · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01004809 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 19 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01004809.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing